Loading patent…
AssigneeLipella Paharmaceuticals Inc.
InventorsMichael B. Chancellor, Hann-Chorng Kuo
Estimating the term…
It has been discovered that cytokines, chemokines, and growth factors in urine are biomarkers indicative of urological disorders including interstitial cystitis/painful bladder syndrome and overactive bladder syndrome. Preferred chemokine biomarkers are CCL2, CCL4 (MIP-1β), CCL11, CXCL1 (GRO-α), sCD40L, IL-12p70/p40, IL-5, sIL-2Rα, IL-6, IL-10, IL-8, and EGF. The concentration of one or more of these chemokines in an urine sample can be used to assist in the diagnosis of urological disorders. Methods for evaluating the effectiveness of treatments for urological disorders and for assessing the severity of urological disorders are also provided.
A method for diagnosing or assisting in the diagnosis of an urological disorder comprising
A kit designed for facilitating the diagnosis an urological disorder comprising
A method for treating an urological disorder comprising administering an effective amount of an antagonist of a chemokine or cytokine relevant to an urological disorder to reduce inflammation in bladder relative to a control.
Dependencies are inferred from the claim text.